


Buy EUR 135.00 Price EUR 66.95 Upside 101.6 %	Value Indicators: EUR DCF: 135.00	Warburg Risk Score: 3.3 Balance Sheet Score: 4.0 Market Liquidity Score: 2.5	Description: Custom software and digital engineering
	Market Snapshot: EUR m Market cap: 887.9 No. of shares (m): 13.3 EV: 935.9 Freefloat MC: 624.2 Ø Trad. Vol. (30d): 4.25 m	Shareholders: Freefloat 70.30 % Carl G. Duerschmidt 20.00 % Detlef Dinsel 9.70 %	Key Figures (WRe): 2024e Beta: 1.1 Price / Book: 3.6 x Equity Ratio: 33 % Net Fin. Debt / EBITDA: 0.8 x Net Debt / EBITDA: 0.9 x

First Glance: Postponement of reporting date weighs on sentiment

- On Friday, Nagarro announced the postponement of the publication of its annual results and annual report via an ad hoc announcement.
- Preliminary results will be published tomorrow. Nagarro reiterated its expectation of achieving its financial targets for 2024.
- The audited financial report will be published on May 15 as additional time is required to complete the audit process with the new auditor. In particular, the additional time is required to assess matters related to the timing of revenue recognition. While the previous approach was in line with IFRS standards, Nagarro will pursue a more complex approach in the future. However, as approximately 90% of Nagarro's revenue is billed as time and material, we assume that the impact from the accounting change should not be significant.
- Based on the application of a corrected approach to the purchase price allocations for acquisitions and the treatment of earn-out liabilities, there will be a reduction in goodwill, an increase in other intangible assets, and a reduction in liabilities. This will impact the 2023 income statement but will not affect the adjusted EBITDA for 2023. Our understanding is that the correction is related to the fact that IFRS treats earn-outs as wages when sellers stay employed.
- The delay in the publication of the audited annual report is expected to result in the temporary exclusion of Nagarro shares from the TecDAX and SDAX indices and looks set to impact the share price.
- Nagarro has confirmed its intention to propose a dividend distribution to shareholders amounting to between 10% and 20% of EBIT, subject to approval at the AGM, which has been rescheduled for 30 June 2025.
- Conclusion:** While we do not expect a large impact from the topics that are currently delaying the reporting, sentiment is clearly impacted and is likely to impact the share price development in the foreseeable time.



Rel. Performance vs SDAX:

1 month:	-10.9 %
6 months:	-40.4 %
Year to date:	-29.2 %
Trailing 12 months:	-13.8 %

Company events:

29.04.25	FY 2024
15.05.25	Q1
14.08.25	Q2
14.11.25	Q3

FY End: 31.12. in EUR m	CAGR (23-26e)	2020	2021	2022	2023	2024e	2025e	2026e
Sales	7.4 %	430.4	546.0	856.3	912.1	960.0	1,027.2	1,129.9
Change Sales yoy		6.9 %	26.9 %	56.8 %	6.5 %	5.3 %	7.0 %	10.0 %
EBITDA adj.		76.2	79.7	148.5	126.1	136.4	146.4	162.8
Margin		17.7 %	14.6 %	17.3 %	13.8 %	14.2 %	14.3 %	14.4 %
EBITDA	8.0 %	66.2	70.3	145.6	121.3	127.4	136.4	152.8
Margin		15.4 %	12.9 %	17.0 %	13.3 %	13.3 %	13.3 %	13.5 %
EBIT	8.9 %	44.5	45.7	112.4	86.2	91.6	98.3	111.3
Margin		10.3 %	8.4 %	13.1 %	9.5 %	9.5 %	9.6 %	9.9 %
Net income before minorities		24.4	30.0	77.3	52.1	61.1	66.5	75.8
Net income	13.3 %	18.4	30.0	77.3	52.1	61.1	66.5	75.8
EPS	13.7 %	n.a.	2.51	5.58	3.87	4.58	4.99	5.69
DPS		n.a.	0.00	0.00	0.00	0.40	0.50	0.60
Dividend Yield		n.a.	n.a.	n.a.	n.a.	0.6 %	0.8 %	0.9 %
FCFPS		4.48	1.81	4.09	3.39	6.06	4.88	4.84
FCF / Market cap		n.a.	1.5 %	3.4 %	3.8 %	9.1 %	7.3 %	7.3 %
EV / Sales		n.a.	3.0 x	2.1 x	1.5 x	1.0 x	0.9 x	0.8 x
EV / EBIT adj.		n.a.	33.8 x	15.6 x	15.4 x	10.5 x	9.1 x	7.6 x
EV / EBIT		n.a.	35.4 x	16.4 x	16.2 x	10.9 x	9.5 x	7.8 x
P / E		n.a.	48.9 x	21.8 x	23.0 x	14.6 x	13.4 x	11.7 x
Net Debt		87.8	149.7	155.8	200.6	112.1	48.0	-16.5
ROCE (NOPAT)		20.5 %	18.8 %	30.1 %	18.3 %	17.7 %	19.5 %	21.5 %
Guidance:	2025: revenue: EUR 1,020-1,080m; adj. EBITDA margin: 14.5-15.5%							

Analyst


Andreas Wolfawolf@warburg-research.com
+49 40 309537-140

FIRST GLANCE

Published 28.04.2025 08:15


1

Sales development
in EUR m




Source: Warburg Research

Customer split
2023



Source: Company

IT engineers by region
2023



Source: Warburg Research


Company Background

- Nagarro provides technology and custom software development services for digital transformation,...
- ...with a focus on disruptive technologies such as artificial intelligence, big data, and internet of things.
- Complementary business fields such as managed services, e-commerce solutions or ERP consulting complete the offering.
- While the majority of revenue is generated in higher price countries, Nagarro is able to serve this demand with access to experts in regions associated with lower costs.

Competitive Quality


- Nagarro is a trusted and valued digitalisation partner developing tailor-made software to achieve competitive differentiation for its clients.
- Technological focus and expertise position the company as an IT engineering expert rather than a consulting or services company.
- Proprietary software Ginger supports collaboration, a decentralised organisational structure which provides access to IT talent and enables Nagarro to serve both, small and large companies around the globe.
- Organizational design and processes allow Nagarro to cross-fertilize knowledge across the global organisation and adapt quickly to new technologies and client needs with lean and agile teams and short time-to-market.
- Access to scarce IT specialists: Nagarro's approx. 17,000 IT experts e.g. in India, China or Romania have a strong footprint in future-oriented technologies such as cloud, AI, IoT, deep learning or big data.

Sales by region
2023; in %



Source: Warburg Research

Revenue by contract type
2023



Source: Warburg Research

DCF model

	Detailed forecast period			Transitional period										Term. Value
Figures in EUR m	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	
Sales	960.0	1,027.2	1,129.9	1,265.5	1,408.3	1,557.6	1,712.8	1,873.3	2,038.3	2,207.0	2,378.8	2,552.8	2,603.8	2.0 %
Sales change	5.3 %	7.0 %	10.0 %	12.0 %	11.3 %	10.6 %	10.0 %	9.4 %	8.8 %	8.3 %	7.8 %	7.3 %	2.0 %	
EBIT	91.6	98.3	111.3	139.2	147.9	163.5	179.8	196.7	214.0	231.7	249.8	268.0	273.4	10.5 %
EBIT-margin	9.5 %	9.6 %	9.9 %	11.0 %	10.5 %	10.5 %	10.5 %	10.5 %	10.5 %	10.5 %	10.5 %	10.5 %	10.5 %	
Tax rate (EBT)	28.0 %	28.0 %	28.0 %	32.0 %	32.0 %	32.0 %	32.0 %	32.0 %	32.0 %	32.0 %	32.0 %	32.0 %	32.0 %	182
NOPAT	65.9	70.8	80.1	94.7	100.5	111.2	122.3	133.8	145.5	157.6	169.8	182.3	185.9	
Depreciation	35.8	38.1	41.5	13.9	14.1	15.6	17.1	18.7	20.4	22.1	23.8	25.5	28.6	59.62 %
in % of Sales	3.7 %	3.7 %	3.7 %	1.1 %	1.0 %	1.0 %	1.0 %	1.0 %	1.0 %	1.0 %	1.0 %	1.0 %	1.1 %	
Changes in provisions	-7.8	1.0	0.0	1.2	1.3	1.3	1.4	1.4	1.5	1.5	1.5	1.5	0.5	1,221
Change in Liquidity from														
- Working Capital	-20.7	3.5	13.2	44.2	21.4	22.4	23.3	24.1	24.7	25.3	25.8	26.1	7.7	10.01 %
- Capex	7.4	7.9	8.5	13.9	15.5	17.1	18.8	20.6	22.4	24.3	26.2	28.1	28.6	
Capex in % of Sales	0.8 %	0.8 %	0.8 %	1.1 %	1.1 %	1.1 %	1.1 %	1.1 %	1.1 %	1.1 %	1.1 %	1.1 %	1.1 %	30.37 %
- Other	26.4	28.2	31.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	80.9	70.3	68.8	51.7	79.0	88.6	98.7	109.2	120.2	131.6	143.2	155.2	178.7	59.62 %
PV of FCF	80.9	65.1	59.1	41.1	58.2	60.4	62.3	63.9	65.1	66.0	66.6	66.8	71.3	
share of PVs	10.01 %			30.37 %										

Model parameter

Derivation of WACC:

Debt ratio	16.00 %
Cost of debt (after tax)	2.4 %
Market return	8.25 %
Risk free rate	2.75 %

WACC 7.96 %

Derivation of Beta:

Financial Strength	1.14
Liquidity (share)	1.14
Cyclicality	1.14
Transparency	1.14
Others	1.14

Beta 1.14

Valuation (m)

Present values 2036e

Terminal Value	1,221
Financial liabilities	294
Pension liabilities	17
Hybrid capital	0
Minority interest	0
Market val. of investments	0
Liquidity	60

Equity Value 1,797

No. of shares (m) 13.3

Value per share (EUR) 134.89

Sensitivity Value per Share (EUR)

Beta WACC		Terminal Growth							Beta WACC		Delta EBIT-margin						
		1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %			-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.36	9.0 %	103.31	105.44	107.71	110.15	112.77	115.59	118.63	1.36	9.0 %	89.72	96.53	103.34	110.15	116.96	123.77	130.57
1.25	8.5 %	113.20	115.77	118.54	121.52	124.74	128.23	132.03	1.25	8.5 %	99.37	106.75	114.14	121.52	128.90	136.29	143.67
1.19	8.2 %	118.70	121.55	124.61	127.92	131.51	135.42	139.68	1.19	8.2 %	104.80	112.51	120.22	127.92	135.63	143.34	151.05
1.14	8.0 %	124.64	127.79	131.20	134.89	138.90	143.28	148.08	1.14	8.0 %	110.71	118.77	126.83	134.89	142.95	151.01	159.06
1.09	7.7 %	131.06	134.56	138.36	142.48	146.99	151.93	157.36	1.09	7.7 %	117.16	125.60	134.04	142.48	150.93	159.37	167.81
1.03	7.5 %	138.02	141.93	146.17	150.80	155.88	161.47	167.65	1.03	7.5 %	124.22	133.08	141.94	150.80	159.66	168.52	177.38
0.92	7.0 %	153.86	158.76	164.13	170.04	176.58	183.85	191.99	0.92	7.0 %	140.56	150.39	160.21	170.04	179.87	189.70	199.52

▪ Slight EBIT margin expansion anticipated

▪ Other: IFRS 16 impact in the detailed forecast. Depreciation and capex at same levels thereafter.

Valuation							
	2020	2021	2022	2023	2024e	2025e	2026e
Price / Book	n.a.	15.2 x	10.2 x	6.6 x	3.6 x	3.0 x	2.4 x
Book value per share ex intangibles	n.a.	-5.90	-3.79	-4.97	-0.22	3.73	9.66
EV / Sales	n.a.	3.0 x	2.1 x	1.5 x	1.0 x	0.9 x	0.8 x
EV / EBITDA	n.a.	23.0 x	12.6 x	11.5 x	7.8 x	6.9 x	5.7 x
EV / EBIT	n.a.	35.4 x	16.4 x	16.2 x	10.9 x	9.5 x	7.8 x
EV / EBIT adj.*	n.a.	33.8 x	15.6 x	15.4 x	10.5 x	9.1 x	7.6 x
P / FCF	n.a.	67.9 x	29.7 x	26.2 x	11.0 x	13.6 x	13.8 x
P / E	n.a.	48.9 x	21.8 x	23.0 x	14.6 x	13.4 x	11.7 x
P / E adj.*	n.a.	48.9 x	21.8 x	23.0 x	14.6 x	13.4 x	11.7 x
Dividend Yield	n.a.	n.a.	n.a.	n.a.	0.6 %	0.8 %	0.9 %
FCF Potential Yield (on market EV)	n.a.	2.5 %	5.2 %	5.1 %	7.0 %	8.8 %	10.6 %
*Adjustments made for: -							

Company Specific Items							
	2020	2021	2022	2023	2024e	2025e	2026e
gross profit (company reporting)	140.2	154.4	247.1	235.7	333.4	352.8	393.5
gross margin (company reporting)	32.6 %	28.3 %	28.9 %	25.8 %	34.7 %	34.3 %	34.8 %

Consolidated profit & loss

In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Sales	430.4	546.0	856.3	912.1	960.0	1,027.2	1,129.9
Change Sales yoy	6.9 %	26.9 %	56.8 %	6.5 %	5.3 %	7.0 %	10.0 %
Increase / decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Own work capitalised	0.3	0.2	0.3	0.3	2.2	2.5	2.5
Material expenses	49.2	59.1	77.0	73.1	69.1	78.1	80.2
Personnel expenses	271.7	373.0	571.1	654.7	693.1	732.4	802.2
Other operating income	11.6	14.8	28.2	32.2	17.0	10.0	10.0
Other operating expenses	53.3	55.5	89.0	91.3	83.5	87.3	101.7
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	66.2	70.3	145.6	121.3	127.4	136.4	152.8
<i>Margin</i>	<i>15.4 %</i>	<i>12.9 %</i>	<i>17.0 %</i>	<i>13.3 %</i>	<i>13.3 %</i>	<i>13.3 %</i>	<i>13.5 %</i>
Depreciation of fixed assets	16.9	19.9	25.5	29.6	31.1	33.3	36.7
EBITA	49.3	50.3	120.1	91.7	96.3	103.1	116.1
Amortisation of intangible assets	4.7	4.7	7.6	5.5	4.7	4.8	4.8
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	44.5	45.7	112.4	86.2	91.6	98.3	111.3
<i>Margin</i>	<i>10.3 %</i>	<i>8.4 %</i>	<i>13.1 %</i>	<i>9.5 %</i>	<i>9.5 %</i>	<i>9.6 %</i>	<i>9.9 %</i>
EBIT adj.	48.0	47.8	117.8	91.1	95.6	102.3	115.3
Interest income	0.5	0.4	0.5	1.8	0.2	0.0	0.0
Interest expenses	7.3	7.8	11.2	18.2	7.0	6.0	6.0
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	37.7	38.2	101.7	69.8	84.8	92.3	105.3
<i>Margin</i>	<i>8.8 %</i>	<i>7.0 %</i>	<i>11.9 %</i>	<i>7.7 %</i>	<i>8.8 %</i>	<i>9.0 %</i>	<i>9.3 %</i>
Total taxes	13.4	8.2	24.4	17.7	23.7	25.8	29.5
Net income from continuing operations	24.4	30.0	77.3	52.1	61.1	66.5	75.8
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	24.4	30.0	77.3	52.1	61.1	66.5	75.8
Minority interest	5.9	0.0	0.0	0.0	0.0	0.0	0.0
Net income	18.4	30.0	77.3	52.1	61.1	66.5	75.8
<i>Margin</i>	<i>4.3 %</i>	<i>5.5 %</i>	<i>9.0 %</i>	<i>5.7 %</i>	<i>6.4 %</i>	<i>6.5 %</i>	<i>6.7 %</i>
Number of shares, average	n.a.	12.0	13.8	13.5	13.3	13.3	13.3
EPS	n.a.	2.51	5.58	3.87	4.58	4.99	5.69
EPS adj.	n.a.	2.51	5.58	3.87	4.58	4.99	5.69


*Adjustments made for:

Guidance: 2025: revenue: EUR 1,020-1,080m; adj. EBITDA margin: 14.5-15.5%


Financial Ratios

	2020	2021	2022	2023	2024e	2025e	2026e
Total Operating Costs / Sales	84.7 %	87.2 %	83.0 %	86.7 %	87.0 %	87.0 %	86.7 %
Operating Leverage	0.7 x	0.1 x	2.6 x	-3.6 x	1.2 x	1.0 x	1.3 x
EBITDA / Interest expenses	9.1 x	9.0 x	13.0 x	6.7 x	18.2 x	22.7 x	25.5 x
Tax rate (EBT)	35.5 %	21.5 %	24.0 %	25.3 %	28.0 %	28.0 %	28.0 %
Dividend Payout Ratio	n.a.	0.0 %	0.0 %	0.0 %	8.7 %	10.0 %	10.5 %
Sales per Employee	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.


Sales, EBITDA in EUR m



Operating Performance in %



Performance per Share



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research


Consolidated balance sheet

In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Assets							
Goodwill and other intangible assets	106.9	178.7	217.4	247.3	247.2	247.1	247.0
thereof other intangible assets	11.0	14.0	13.6	26.5	26.4	26.3	26.2
thereof Goodwill	95.9	163.4	202.6	220.8	220.8	220.8	220.8
Property, plant and equipment	6.4	11.1	11.4	12.9	13.9	15.0	16.2
Financial assets	3.0	3.7	4.0	3.3	3.3	3.3	3.3
Other long-term assets	51.7	59.3	52.3	47.6	47.3	50.8	56.3
Fixed assets	168.0	253.0	285.1	311.3	311.7	316.3	322.9
Inventories	0.1	0.3	0.3	0.0	0.4	0.5	0.5
Accounts receivable	73.9	103.3	156.8	182.5	202.5	211.1	232.2
Liquid assets	107.7	106.6	110.2	110.1	171.7	236.8	301.3
Other short-term assets	37.1	61.7	66.7	76.0	77.0	84.0	84.0
Current assets	218.8	271.9	333.9	368.6	451.6	532.4	618.0
Total Assets	386.8	524.9	619.0	679.9	763.3	848.6	940.9
Liabilities and shareholders' equity							
Shareholders' equity	43.8	96.8	165.5	181.1	244.3	296.8	375.7
Minority interest	2.7	0.0	0.0	0.0	5.0	20.0	20.0
Total equity	46.5	96.8	165.5	181.1	249.3	316.8	395.7
Provisions	33.2	45.3	55.8	59.4	43.0	46.0	46.0
thereof provisions for pensions and similar obligations	6.0	10.1	12.9	16.8	9.0	10.0	10.0
Financial liabilities (total)	189.5	246.1	253.1	293.9	274.7	274.7	274.7
Short-term financial liabilities	14.4	23.8	11.5	6.2	6.2	6.2	6.2
Accounts payable	22.2	18.5	15.3	17.9	50.0	53.5	58.8
Other liabilities	95.4	118.2	129.4	127.5	146.3	157.5	165.6
Liabilities	340.3	428.0	453.5	498.8	514.0	531.8	545.1
Total liabilities and shareholders' equity	386.8	524.9	619.0	679.9	763.3	848.6	940.9


Financial Ratios

	2020	2021	2022	2023	2024e	2025e	2026e
Efficiency of Capital Employment							
Operating Assets Turnover	8.8 x	6.3 x	6.1 x	5.6 x	6.7 x	7.0 x	7.0 x
Capital Employed Turnover	3.2 x	2.2 x	2.7 x	2.4 x	2.7 x	2.8 x	3.0 x
ROA	11.0 %	11.9 %	27.1 %	16.8 %	19.6 %	21.0 %	23.5 %
Return on Capital							
ROCE (NOPAT)	20.5 %	18.8 %	30.1 %	18.3 %	17.7 %	19.5 %	21.5 %
ROE	39.2 %	42.7 %	58.9 %	30.1 %	28.7 %	24.6 %	22.5 %
Adj. ROE	39.2 %	42.7 %	58.9 %	30.1 %	28.7 %	24.6 %	22.5 %
Balance sheet quality							
Net Debt	87.8	149.7	155.8	200.6	112.1	48.0	-16.5
Net Financial Debt	81.8	139.5	142.9	183.8	103.1	38.0	-26.5
Net Gearing	188.7 %	154.6 %	94.1 %	110.8 %	45.0 %	15.1 %	-4.2 %
Net Fin. Debt / EBITDA	123.6 %	198.6 %	98.2 %	151.6 %	80.9 %	27.8 %	n.a.
Book Value / Share	n.a.	7.0	12.1	13.6	18.3	22.3	28.2
Book value per share ex intangibles	n.a.	-5.9	-3.8	-5.0	-0.2	3.7	9.7


ROCE Development



Net debt in EUR m



Book Value per Share in EUR



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research

Consolidated cash flow statement


In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Net income	24.4	30.0	77.3	52.1	61.1	66.5	75.8
Depreciation of fixed assets	16.9	19.9	25.5	29.6	31.1	33.3	36.7
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	4.7	4.7	7.6	5.5	4.7	4.8	4.8
Increase/decrease in long-term provisions	1.2	1.3	1.9	2.7	-7.8	1.0	0.0
Other non-cash income and expenses	6.6	8.7	18.4	9.7	0.0	0.0	0.0
Cash Flow before NWC change	53.8	64.5	130.7	99.6	89.1	105.6	117.3
Increase / decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in accounts receivable	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in accounts payable	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in other working capital positions	18.4	-20.6	-48.4	-21.9	25.4	-4.4	-13.2
Increase / decrease in working capital (total)	18.4	-20.6	-48.4	-21.9	25.4	-4.4	-13.2
Net cash provided by operating activities [1]	72.2	44.0	82.3	77.7	114.5	101.2	104.0
Investments in intangible assets	-1.0	-0.8	-0.6	-1.5	-1.6	-1.7	-1.7
Investments in property, plant and equipment	-2.6	-1.9	-3.5	-5.4	-5.8	-6.2	-6.8
Payments for acquisitions	-7.8	-50.1	-40.4	-54.3	0.0	0.0	0.0
Financial investments	1.2	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.1	0.0	0.1	-2.5	0.0	0.0	0.0
Net cash provided by investing activities [2]	-10.1	-52.8	-44.5	-63.7	-7.4	-7.9	-8.5
Change in financial liabilities	23.9	18.2	11.4	62.3	-19.2	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of own shares	0.0	0.0	-10.0	-29.7	0.0	0.0	0.0
Capital measures	0.1	6.1	0.0	0.0	0.0	0.0	0.0
Other	-17.5	-24.2	-30.2	-39.3	-26.4	-28.2	-31.1
Net cash provided by financing activities [3]	6.5	0.0	-28.8	-6.7	-45.6	-28.2	-31.1
Change in liquid funds [1]+[2]+[3]	68.6	-8.8	9.0	7.3	61.6	65.1	64.5
Effects of exchange-rate changes on cash	-1.4	0.6	-1.3	-2.6	0.0	0.0	0.0
Cash and cash equivalent at end of period	110.9	99.6	114.3	114.8	171.7	236.8	301.3

Financial Ratios

	2020	2021	2022	2023	2024e	2025e	2026e
Cash Flow							
FCF	51.0	21.6	56.6	45.7	80.8	65.1	64.5
Free Cash Flow / Sales	11.9 %	4.0 %	6.6 %	5.0 %	8.4 %	6.3 %	5.7 %
Free Cash Flow Potential	49.2	39.7	95.5	71.6	70.0	82.3	92.2
Free Cash Flow / Net Profit	276.6 %	72.1 %	73.3 %	87.7 %	132.3 %	97.9 %	85.1 %
Interest Received / Avg. Cash	0.7 %	0.4 %	0.5 %	1.6 %	0.1 %	0.0 %	0.0 %
Interest Paid / Avg. Debt	4.6 %	3.6 %	4.5 %	6.6 %	2.5 %	2.2 %	2.2 %
Management of Funds							
Investment ratio	0.8 %	0.5 %	0.5 %	0.8 %	0.8 %	0.8 %	0.8 %
Maint. Capex / Sales	0.8 %	0.5 %	0.5 %	0.8 %	0.8 %	0.0 %	0.0 %
Capex / Dep	16.5 %	10.9 %	12.5 %	19.6 %	20.5 %	20.6 %	20.5 %
Avg. Working Capital / Sales	11.5 %	10.8 %	11.9 %	15.2 %	14.5 %	12.7 %	12.3 %
Trade Debtors / Trade Creditors	332.8 %	559.6 %	1028.2 %	1017.4 %	405.0 %	394.6 %	394.9 %
Inventory Turnover	387.1 x	219.6 x	291.6 x	73124.0 x	172.8 x	156.1 x	160.4 x
Receivables collection period (days)	63	69	67	73	77	75	75
Payables payment period (days)	165	114	72	90	264	250	268
Cash conversion cycle (Days)	-172	-102	-70	-91	-312	-293	-319


CAPEX and Cash Flow

in EUR m




Source: Warburg Research

Free Cash Flow Generation



Source: Warburg Research

Working Capital



Source: Warburg Research

LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
3. CIC (Crédit Industriel et Commercial) and M.M.Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- 1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- 2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- 3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- 4- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.
- 5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- 6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- 6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- 6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- 7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Nagarro	3, 5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A3H2200.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
“-“	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	145	73
Hold	43	22
Sell	6	3
Rating suspended	5	3
Total	199	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	37	74
Hold	9	18
Sell	1	2
Rating suspended	3	6
Total	50	100

PRICE AND RATING HISTORY NAGARRO AS OF 28.04.2025



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Matthias Rode +49 40 3282-2678
Head of Equities mrode@mmwarburg.com

RESEARCH

Michael Heider +49 40 309537-280
Head of Research mheider@warburg-research.com

Henner Rüschemeyer +49 40 309537-270
Head of Research hrueschmeier@warburg-research.com

Stefan Augustin +49 40 309537-168
Cap. Goods, Engineering saugustin@warburg-research.com

Jan Bauer +49 40 309537-155
Renewables jbauer@warburg-research.com

Christian Cohrs +49 40 309537-175
Industrials & Transportation ccohrs@warburg-research.com

Dr. Christian Ehmann +49 40 309537-167
BioTech, Life Science cehmann@warburg-research.com

Felix Ellmann +49 40 309537-120
Software, IT fellmann@warburg-research.com

Jörg Philipp Frey +49 40 309537-258
Retail, Consumer Goods jfrey@warburg-research.com

Marius Fuhrberg +49 40 309537-185
Financial Services mfuhrberg@warburg-research.com

Fabio Hölscher +49 40 309537-240
Automobiles, Car Suppliers fhoelscher@warburg-research.com

Philipp Kaiser +49 40 309537-260
Real Estate, Construction pkaiser@warburg-research.com

Thilo Kleibauer +49 40 309537-257
Retail, Consumer Goods tkleibauer@warburg-research.com

Hannes Müller +49 40 309537-255
Software, IT hmueller@warburg-research.com

Andreas Pläsier +49 40 309537-246
Banks, Financial Services aplaesier@warburg-research.com

Malte Schaumann +49 40 309537-170
Technology mschaumann@warburg-research.com

Oliver Schwarz +49 40 309537-250
Chemicals, Agriculture oschwarz@warburg-research.com

Simon Stippig +49 40 309537-265
Real Estate, Telco sstippig@warburg-research.com

Marc-René Tonn +49 40 309537-259
Automobiles, Car Suppliers mtonn@warburg-research.com

Robert-Jan van der Horst +49 40 309537-290
Technology rvanderhorst@warburg-research.com

Andreas Wolf +49 40 309537-140
Software, IT awolf@warburg-research.com

INSTITUTIONAL EQUITY SALES

Klaus Schilling +49 69 5050-7400
Head of Equity Sales, Germany kschilling@mmwarburg.com

Tim Beckmann +49 40 3282-2665
United Kingdom tbeckmann@mmwarburg.com

Jens Buchmüller +49 69 5050-7415
Scandinavia, Austria jbuchmueller@mmwarburg.com

Matthias Fritsch +49 40 3282-2696
United Kingdom, Ireland mfritsch@mmwarburg.com

Rudolf Alexander Michaelis +49 40 3282-2649
Germany rmichaelis@mmwarburg.com

Roman Alexander Niklas +49 69 5050-7412
Switzerland, Poland, Italy rniklas@mmwarburg.com

Sascha Propp +49 40 3282-2656
France spropp@mmwarburg.com

Leyan Ilkbahar +49 40 3282-2695
Roadshow/Marketing lilkbahar@mmwarburg.com

Antonia Möller +49 69 5050-7417
Roadshow/Marketing amoeller@mmwarburg.com

Juliane Niemann +49 40 3282-2694
Roadshow/Marketing jniemann@mmwarburg.com

SALES TRADING

Oliver Merckel +49 40 3282-2634
Head of Sales Trading omerckel@mmwarburg.com

Bastian Quast +49 40 3282-2701
Sales Trading bquast@mmwarburg.com

Christian Salomon +49 40 3282-2685
Sales Trading csalomon@mmwarburg.com

DESIGNATED SPONSORING

Sebastian Schulz +49 40 3282-2631
Designated Sponsoring sschulz@mmwarburg.com

Jörg Treptow +49 40 3282-2658
Designated Sponsoring jtreptow@mmwarburg.com

MACRO RESEARCH

Carsten Klude +49 40 3282-2572
Macro Research cklude@mmwarburg.com

Dr. Christian Jasperneite +49 40 3282-2439
Investment Strategy cjasperneite@mmwarburg.com

Our research can be found under:

Warburg Research research.mmwarburg.com/en/index.html
Bloomberg RESP MMWA GO
FactSet www.factset.com

LSEG www.lseg.com
Capital IQ www.capitaliq.com

For access please contact:

Andrea Schaper +49 40 3282-2632
Sales Assistance aschaper@mmwarburg.com

Kerstin Muthig +49 40 3282-2703
Sales Assistance kmuthig@mmwarburg.com